Biomedical Engineering Reference
In-Depth Information
88. Chou DK, Krishnamurthy R, Randolph, T.W, Carpenter JF,
Manning MC. (2005) Effects of Tween 20 and Tween 80 on the
stability of Albutropin
1
during agitation. J. Pharm. Sci. 94,
1368-1381.
89. Zhao HL, Yao XQ, Xue C, Wang Y, Xiong XH, Liu ZM. (2008)
Increasing the homogeneity, stability and activity of human
serum albumin and interferon-
a
2b fusion protein by linker
engineering. Protein Expr. Purif. 61, 73-77.
90. Schulte S. (2009) Half-life extension through albumin fusion
technologies. Thromb. Res. 124(Suppl. 2), S6-S8.
91. Sheffield WP, Wilson B, Eltringham-Smith LJ, Gataiance S,
Bhakta V. (2005) Recombinant albumins containing additional
peptide sequences smaller than barbourin retain the ability of
barbourin-albumin to inhibit platelet aggregation. Thromb.
Haemost. 93, 914-921.
92. Eichler P, Friesen HJ, Lubenow N, Jaeger B, Greinacher A.
(2000) Antihirudin antibodies in patients with heparin-induced
thrombocytopenia treated with lepirudin: incidence, effects on
aPTT, and clinical relevance. Blood 96, 2373-2378.
93. Fischer KG, Liebe V, Hudek R, Piazolo L, Haase KK, Borg-
grefe M, et al. (2003) Anti-hirudin antibodies alter pharmaco-
kinetics and pharmacodynamics of
recombinant hirudin.
Thromb. Haemost. 89, 973-982.
94. Baker MP, Jones TD. (2007) Identification and removal of
immunogenicity in therapeutic proteins. Curr. Opin. Drug
Discov. Dev. 10, 219-227.
95. De Groot AS, Scott DW. (2007) Immunogenicity of protein
therapeutics. Trends Immunol. 28, 482-490.
Search WWH ::
Custom Search